Arexera Therapeutics Highlights Potentially Best-in-Class Preclinical Profile and Initiates Clinical Development for ATL-101 in Huntington’s Disease
ATL-101 achieved robust (~80%) and durable (> 6 months after single administration) HTT lowering in the striatum, the key region of the brain in Huntington’s disease (HD), in non-human primates…
Read more